Annual Income Statements for Global Medical REIT
This table shows Global Medical REIT's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.
Quarterly Income Statements for Global Medical REIT
This table shows Global Medical REIT's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.
Metric |
|
Q3 2022 |
Q4 2022 |
Q1 2023 |
Q2 2023 |
Q3 2023 |
Q4 2023 |
Q1 2024 |
Q2 2024 |
Q3 2024 |
Q4 2024 |
Net Income / (Loss) Attributable to Common Shareholders |
|
8.06 |
0.37 |
0.67 |
12 |
3.14 |
-0.84 |
0.79 |
-3.15 |
1.79 |
1.37 |
Consolidated Net Income / (Loss) |
|
10 |
1.85 |
2.17 |
14 |
4.83 |
0.55 |
2.31 |
-1.95 |
3.39 |
2.94 |
Net Income / (Loss) Continuing Operations |
|
3.28 |
1.85 |
1.69 |
1.39 |
2.54 |
1.42 |
2.31 |
1.43 |
1.57 |
-1.11 |
Total Pre-Tax Income |
|
3.28 |
1.85 |
1.69 |
1.39 |
2.54 |
1.42 |
2.31 |
1.43 |
1.57 |
-1.11 |
Total Revenue |
|
28 |
28 |
28 |
28 |
28 |
26 |
28 |
27 |
27 |
28 |
Net Interest Income / (Expense) |
|
-6.96 |
-8.07 |
-8.27 |
-8.47 |
-7.17 |
-6.98 |
-6.89 |
-6.99 |
-7.24 |
-7.57 |
Total Interest Expense |
|
6.96 |
8.07 |
8.27 |
8.47 |
7.17 |
6.98 |
6.89 |
6.99 |
7.24 |
7.57 |
Long-Term Debt Interest Expense |
|
6.96 |
8.07 |
8.27 |
8.47 |
7.17 |
6.98 |
6.89 |
6.99 |
7.24 |
7.57 |
Total Non-Interest Income |
|
35 |
36 |
36 |
36 |
36 |
33 |
35 |
34 |
34 |
35 |
Other Service Charges |
|
0.06 |
0.02 |
0.03 |
0.03 |
0.02 |
0.03 |
0.05 |
0.03 |
0.09 |
0.21 |
Other Non-Interest Income |
|
35 |
36 |
36 |
36 |
35 |
33 |
35 |
34 |
34 |
35 |
Total Non-Interest Expense |
|
25 |
26 |
26 |
26 |
26 |
25 |
26 |
26 |
25 |
29 |
Other Operating Expenses |
|
11 |
11 |
11 |
12 |
12 |
10 |
12 |
12 |
12 |
15 |
Depreciation Expense |
|
10 |
11 |
10 |
10 |
10 |
10 |
10 |
10 |
9.99 |
10 |
Amortization Expense |
|
4.29 |
4.51 |
4.40 |
4.34 |
4.10 |
4.04 |
3.97 |
3.87 |
3.65 |
3.45 |
Restructuring Charge |
|
0.11 |
0.11 |
0.04 |
0.00 |
0.00 |
- |
0.00 |
0.00 |
0.00 |
0.16 |
Net Income / (Loss) Discontinued Operations |
|
6.75 |
- |
0.49 |
13 |
2.29 |
- |
0.00 |
-3.38 |
1.82 |
5.77 |
Preferred Stock Dividends Declared |
|
1.46 |
1.46 |
1.46 |
1.46 |
1.46 |
1.46 |
1.46 |
1.46 |
1.46 |
1.46 |
Net Income / (Loss) Attributable to Noncontrolling Interest |
|
0.52 |
0.02 |
0.05 |
0.90 |
0.24 |
-0.07 |
0.07 |
-0.26 |
0.15 |
0.11 |
Basic Earnings per Share |
|
$0.12 |
$0.01 |
$0.01 |
$0.18 |
$0.05 |
($0.01) |
$0.01 |
($0.05) |
$0.03 |
$0.02 |
Weighted Average Basic Shares Outstanding |
|
65.52M |
65.46M |
65.53M |
65.54M |
65.57M |
65.55M |
65.57M |
65.59M |
65.74M |
65.94M |
Diluted Earnings per Share |
|
$0.12 |
$0.01 |
$0.01 |
$0.18 |
$0.05 |
($0.01) |
$0.01 |
($0.05) |
$0.03 |
$0.02 |
Weighted Average Diluted Shares Outstanding |
|
65.52M |
65.46M |
65.53M |
65.54M |
65.57M |
65.55M |
65.57M |
65.59M |
65.74M |
65.94M |
Weighted Average Basic & Diluted Shares Outstanding |
|
65.52M |
65.53M |
65.53M |
65.56M |
65.56M |
65.57M |
65.59M |
65.59M |
66.80M |
66.87M |
Annual Cash Flow Statements for Global Medical REIT
This table details how cash moves in and out of Global Medical REIT's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.
Metric |
2022 |
2023 |
2024 |
Net Change in Cash & Equivalents |
1.70 |
-7.73 |
2.22 |
Net Cash From Operating Activities |
77 |
68 |
70 |
Net Cash From Continuing Operating Activities |
77 |
68 |
70 |
Net Income / (Loss) Continuing Operations |
20 |
22 |
6.69 |
Consolidated Net Income / (Loss) |
20 |
22 |
6.69 |
Depreciation Expense |
40 |
41 |
40 |
Amortization Expense |
20 |
20 |
18 |
Non-Cash Adjustments to Reconcile Net Income |
-1.58 |
-8.99 |
2.99 |
Changes in Operating Assets and Liabilities, net |
-1.74 |
-5.69 |
2.04 |
Net Cash From Investing Activities |
-137 |
68 |
-46 |
Net Cash From Continuing Investing Activities |
-137 |
68 |
-46 |
Purchase of Investment Securities |
-156 |
-11 |
-103 |
Sale and/or Maturity of Investments |
18 |
79 |
57 |
Other Investing Activities, net |
1.00 |
0.00 |
0.00 |
Net Cash From Financing Activities |
62 |
-144 |
-22 |
Net Cash From Continuing Financing Activities |
62 |
-144 |
-22 |
Net Change in Deposits |
-1.97 |
7.16 |
0.25 |
Issuance of Debt |
139 |
83 |
144 |
Issuance of Common Equity |
9.90 |
0.00 |
11 |
Repayment of Debt |
-20 |
-169 |
-111 |
Payment of Dividends |
-64 |
-65 |
-66 |
Cash Interest Paid |
22 |
30 |
27 |
Quarterly Cash Flow Statements for Global Medical REIT
This table details how cash moves in and out of Global Medical REIT's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.
Metric |
|
Q3 2022 |
Q4 2022 |
Q1 2023 |
Q2 2023 |
Q3 2023 |
Q4 2023 |
Q1 2024 |
Q2 2024 |
Q3 2024 |
Q4 2024 |
Net Change in Cash & Equivalents |
|
-0.61 |
0.86 |
-0.47 |
-4.20 |
-2.17 |
-0.89 |
1.08 |
0.01 |
-0.03 |
1.15 |
Net Cash From Operating Activities |
|
18 |
18 |
16 |
18 |
17 |
18 |
14 |
19 |
16 |
21 |
Net Cash From Continuing Operating Activities |
|
18 |
18 |
16 |
18 |
17 |
18 |
14 |
19 |
16 |
21 |
Net Income / (Loss) Continuing Operations |
|
10 |
1.85 |
2.17 |
14 |
4.83 |
0.55 |
2.31 |
-1.95 |
3.39 |
2.94 |
Consolidated Net Income / (Loss) |
|
10 |
1.85 |
2.17 |
14 |
4.83 |
0.55 |
2.31 |
-1.95 |
3.39 |
2.94 |
Depreciation Expense |
|
10 |
11 |
10 |
10 |
10 |
10 |
10 |
10 |
9.99 |
10 |
Amortization Expense |
|
5.06 |
5.38 |
5.27 |
5.19 |
4.87 |
4.79 |
4.68 |
4.58 |
4.39 |
4.26 |
Non-Cash Adjustments to Reconcile Net Income |
|
-5.54 |
1.15 |
0.22 |
-11 |
-0.86 |
3.11 |
1.44 |
5.61 |
-0.61 |
-3.44 |
Changes in Operating Assets and Liabilities, net |
|
-1.36 |
-0.65 |
-2.38 |
-0.50 |
-2.27 |
-0.54 |
-4.25 |
0.57 |
-0.86 |
6.57 |
Net Cash From Investing Activities |
|
-33 |
-1.41 |
3.09 |
62 |
5.66 |
-3.11 |
-2.72 |
1.79 |
-25 |
-20 |
Net Cash From Continuing Investing Activities |
|
-33 |
-1.41 |
3.09 |
62 |
5.66 |
-3.11 |
-2.72 |
1.79 |
-25 |
-20 |
Purchase of Investment Securities |
|
-53 |
-1.89 |
-0.81 |
-2.53 |
-3.86 |
-4.11 |
-2.55 |
-5.21 |
-36 |
-59 |
Sale and/or Maturity of Investments |
|
18 |
0.17 |
4.05 |
64 |
9.53 |
1.00 |
-0.17 |
7.49 |
12 |
38 |
Other Investing Activities, net |
|
1.49 |
0.30 |
-0.15 |
0.15 |
- |
- |
0.00 |
-0.50 |
-0.75 |
1.25 |
Net Cash From Financing Activities |
|
15 |
-16 |
-19 |
-84 |
-25 |
-16 |
-10 |
-21 |
9.16 |
0.15 |
Net Cash From Continuing Financing Activities |
|
15 |
-16 |
-19 |
-84 |
-25 |
-16 |
-10 |
-21 |
9.16 |
0.15 |
Net Change in Deposits |
|
-0.44 |
-0.57 |
-0.64 |
-0.26 |
-0.14 |
8.20 |
-0.06 |
0.31 |
-0.02 |
0.02 |
Issuance of Debt |
|
35 |
12 |
13 |
12 |
14 |
45 |
14 |
25 |
44 |
61 |
Repayment of Debt |
|
-3.53 |
-11 |
-15 |
-80 |
-22 |
-53 |
-8.03 |
-29 |
-30 |
-44 |
Payment of Dividends |
|
-16 |
-16 |
-16 |
-16 |
-16 |
-16 |
-16 |
-16 |
-16 |
-17 |
Cash Interest Paid |
|
6.21 |
6.37 |
8.14 |
8.15 |
7.00 |
6.86 |
6.41 |
6.18 |
6.94 |
7.05 |
Annual Balance Sheets for Global Medical REIT
This table presents Global Medical REIT's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.
Metric |
2022 |
2023 |
2024 |
Total Assets |
1,393 |
1,268 |
1,256 |
Cash and Due from Banks |
4.02 |
1.28 |
6.82 |
Restricted Cash |
10 |
5.45 |
2.13 |
Interest Bearing Deposits at Other Banks |
7.83 |
0.67 |
0.71 |
Trading Account Securities |
35 |
25 |
19 |
Loans and Leases, Net of Allowance |
0.00 |
0.00 |
0.00 |
Premises and Equipment, Net |
1,072 |
974 |
953 |
Deferred Acquisition Cost |
30 |
27 |
28 |
Goodwill |
5.90 |
5.90 |
5.90 |
Intangible Assets |
148 |
139 |
139 |
Other Assets |
81 |
89 |
102 |
Total Liabilities & Shareholders' Equity |
1,393 |
1,268 |
1,256 |
Total Liabilities |
744 |
662 |
701 |
Non-Interest Bearing Deposits |
5.46 |
3.69 |
3.32 |
Short-Term Debt |
636 |
585 |
632 |
Other Short-Term Payables |
30 |
29 |
33 |
Long-Term Debt |
58 |
26 |
14 |
Other Long-Term Liabilities |
15 |
18 |
18 |
Commitments & Contingencies |
0.00 |
0.00 |
0.00 |
Total Equity & Noncontrolling Interests |
649 |
606 |
556 |
Total Preferred & Common Equity |
633 |
584 |
534 |
Preferred Stock |
75 |
75 |
75 |
Total Common Equity |
558 |
509 |
459 |
Common Stock |
722 |
722 |
734 |
Retained Earnings |
-199 |
-239 |
-294 |
Accumulated Other Comprehensive Income / (Loss) |
35 |
25 |
19 |
Noncontrolling Interest |
16 |
22 |
22 |
Quarterly Balance Sheets for Global Medical REIT
This table presents Global Medical REIT's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.
Metric |
|
Q3 2022 |
Q1 2023 |
Q2 2023 |
Q3 2023 |
Q1 2024 |
Q2 2024 |
Q3 2024 |
Total Assets |
|
1,407 |
1,369 |
1,321 |
1,303 |
1,264 |
1,241 |
1,243 |
Cash and Due from Banks |
|
3.20 |
4.60 |
2.46 |
1.28 |
1.33 |
4.98 |
5.72 |
Restricted Cash |
|
10 |
9.38 |
7.33 |
6.33 |
6.47 |
2.84 |
2.07 |
Interest Bearing Deposits at Other Banks |
|
7.66 |
8.63 |
9.73 |
9.86 |
0.74 |
0.93 |
1.69 |
Trading Account Securities |
|
37 |
27 |
36 |
38 |
29 |
28 |
15 |
Loans and Leases, Net of Allowance |
|
0.00 |
0.00 |
0.00 |
0.00 |
0.00 |
0.00 |
0.00 |
Premises and Equipment, Net |
|
1,087 |
1,053 |
1,007 |
988 |
960 |
941 |
948 |
Deferred Acquisition Cost |
|
29 |
30 |
26 |
27 |
28 |
28 |
28 |
Goodwill |
|
5.90 |
5.90 |
5.90 |
5.90 |
5.90 |
5.90 |
5.90 |
Intangible Assets |
|
148 |
148 |
140 |
139 |
139 |
136 |
138 |
Other Assets |
|
78 |
81 |
86 |
87 |
93 |
93 |
98 |
Total Liabilities & Shareholders' Equity |
|
1,407 |
1,369 |
1,321 |
1,303 |
1,264 |
1,241 |
1,243 |
Total Liabilities |
|
742 |
741 |
679 |
669 |
666 |
663 |
678 |
Non-Interest Bearing Deposits |
|
5.40 |
4.69 |
4.21 |
3.91 |
4.38 |
3.97 |
3.22 |
Short-Term Debt |
|
635 |
635 |
568 |
561 |
592 |
599 |
614 |
Other Short-Term Payables |
|
29 |
28 |
32 |
29 |
27 |
28 |
30 |
Long-Term Debt |
|
58 |
57 |
57 |
57 |
26 |
15 |
14 |
Other Long-Term Liabilities |
|
15 |
15 |
19 |
18 |
18 |
17 |
16 |
Total Equity & Noncontrolling Interests |
|
665 |
628 |
641 |
634 |
597 |
578 |
565 |
Total Preferred & Common Equity |
|
649 |
613 |
620 |
611 |
575 |
556 |
543 |
Preferred Stock |
|
75 |
75 |
75 |
75 |
75 |
75 |
75 |
Total Common Equity |
|
574 |
538 |
545 |
536 |
500 |
481 |
468 |
Common Stock |
|
722 |
722 |
722 |
722 |
723 |
723 |
734 |
Retained Earnings |
|
-185 |
-212 |
-214 |
-224 |
-252 |
-269 |
-281 |
Accumulated Other Comprehensive Income / (Loss) |
|
37 |
27 |
36 |
38 |
29 |
28 |
15 |
Noncontrolling Interest |
|
16 |
16 |
22 |
22 |
22 |
22 |
22 |
Annual Metrics And Ratios for Global Medical REIT
This table displays calculated financial ratios and metrics derived from Global Medical REIT's official financial filings.
Metric |
2022 |
2023 |
2024 |
Growth Metrics |
- |
- |
- |
Revenue Growth |
16.43% |
-1.69% |
-0.06% |
EBITDA Growth |
9.83% |
-6.40% |
-8.62% |
EBIT Growth |
-23.33% |
-46.82% |
-40.32% |
NOPAT Growth |
-23.33% |
-46.82% |
-40.32% |
Net Income Growth |
9.02% |
8.69% |
-69.21% |
EPS Growth |
5.26% |
15.00% |
-95.65% |
Operating Cash Flow Growth |
10.98% |
-10.58% |
2.35% |
Free Cash Flow Firm Growth |
17.87% |
218.02% |
-85.58% |
Invested Capital Growth |
10.36% |
-9.39% |
-1.23% |
Revenue Q/Q Growth |
7.41% |
-2.01% |
1.48% |
EBITDA Q/Q Growth |
7.45% |
-2.00% |
-4.68% |
EBIT Q/Q Growth |
22.69% |
-5.73% |
-37.57% |
NOPAT Q/Q Growth |
-16.26% |
-5.73% |
-37.57% |
Net Income Q/Q Growth |
-15.40% |
-5.63% |
55.48% |
EPS Q/Q Growth |
-20.00% |
-8.00% |
150.00% |
Operating Cash Flow Q/Q Growth |
1.36% |
-0.27% |
3.54% |
Free Cash Flow Firm Q/Q Growth |
28.01% |
17.22% |
-70.23% |
Invested Capital Q/Q Growth |
-1.05% |
-2.73% |
0.72% |
Profitability Metrics |
- |
- |
- |
EBITDA Margin |
65.24% |
62.12% |
56.80% |
EBIT Margin |
11.82% |
6.39% |
3.82% |
Profit (Net Income) Margin |
17.85% |
19.73% |
6.08% |
Tax Burden Percent |
150.99% |
308.63% |
159.22% |
Interest Burden Percent |
100.00% |
100.00% |
100.00% |
Effective Tax Rate |
0.00% |
0.00% |
0.00% |
Return on Invested Capital (ROIC) |
1.03% |
0.55% |
0.35% |
ROIC Less NNEP Spread (ROIC-NNEP) |
2.09% |
2.80% |
0.74% |
Return on Net Nonoperating Assets (RNNOA) |
2.07% |
2.91% |
0.80% |
Return on Equity (ROE) |
3.11% |
3.46% |
1.15% |
Cash Return on Invested Capital (CROIC) |
-8.82% |
10.40% |
1.59% |
Operating Return on Assets (OROA) |
1.00% |
0.53% |
0.33% |
Return on Assets (ROA) |
1.51% |
1.63% |
0.53% |
Return on Common Equity (ROCE) |
2.67% |
2.94% |
0.96% |
Return on Equity Simple (ROE_SIMPLE) |
3.16% |
3.72% |
1.25% |
Net Operating Profit after Tax (NOPAT) |
13 |
7.04 |
4.20 |
NOPAT Margin |
11.82% |
6.39% |
3.82% |
Net Nonoperating Expense Percent (NNEP) |
-1.06% |
-2.25% |
-0.40% |
SG&A Expenses to Revenue |
0.00% |
0.00% |
0.00% |
Operating Expenses to Revenue |
88.18% |
93.61% |
96.18% |
Earnings before Interest and Taxes (EBIT) |
13 |
7.04 |
4.20 |
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA) |
73 |
68 |
63 |
Valuation Ratios |
- |
- |
- |
Price to Book Value (P/BV) |
0.93 |
1.30 |
1.12 |
Price to Tangible Book Value (P/TBV) |
1.28 |
1.82 |
1.64 |
Price to Revenue (P/Rev) |
4.62 |
6.01 |
4.68 |
Price to Earnings (P/E) |
38.84 |
44.77 |
635.91 |
Dividend Yield |
10.64% |
8.32% |
10.88% |
Earnings Yield |
2.57% |
2.23% |
0.16% |
Enterprise Value to Invested Capital (EV/IC) |
0.95 |
1.12 |
1.04 |
Enterprise Value to Revenue (EV/Rev) |
11.43 |
12.38 |
11.34 |
Enterprise Value to EBITDA (EV/EBITDA) |
17.51 |
19.92 |
19.97 |
Enterprise Value to EBIT (EV/EBIT) |
96.67 |
193.58 |
297.16 |
Enterprise Value to NOPAT (EV/NOPAT) |
96.67 |
193.58 |
297.16 |
Enterprise Value to Operating Cash Flow (EV/OCF) |
16.73 |
19.92 |
17.83 |
Enterprise Value to Free Cash Flow (EV/FCFF) |
0.00 |
10.24 |
65.04 |
Leverage & Solvency |
- |
- |
- |
Debt to Equity |
1.07 |
1.01 |
1.16 |
Long-Term Debt to Equity |
0.09 |
0.04 |
0.03 |
Financial Leverage |
0.99 |
1.04 |
1.08 |
Leverage Ratio |
2.06 |
2.12 |
2.17 |
Compound Leverage Factor |
2.06 |
2.12 |
2.17 |
Debt to Total Capital |
51.68% |
50.22% |
53.75% |
Short-Term Debt to Total Capital |
47.38% |
48.09% |
52.55% |
Long-Term Debt to Total Capital |
4.29% |
2.13% |
1.20% |
Preferred Equity to Total Capital |
5.58% |
6.16% |
6.24% |
Noncontrolling Interests to Total Capital |
1.20% |
1.83% |
1.81% |
Common Equity to Total Capital |
41.54% |
41.79% |
38.20% |
Debt to EBITDA |
9.49 |
8.93 |
10.33 |
Net Debt to EBITDA |
9.19 |
8.82 |
10.18 |
Long-Term Debt to EBITDA |
0.79 |
0.38 |
0.23 |
Debt to NOPAT |
52.41 |
86.80 |
153.73 |
Net Debt to NOPAT |
50.73 |
85.75 |
151.43 |
Long-Term Debt to NOPAT |
4.35 |
3.68 |
3.43 |
Noncontrolling Interest Sharing Ratio |
14.05% |
15.00% |
16.69% |
Liquidity Ratios |
- |
- |
- |
Cash Flow Metrics |
- |
- |
- |
Free Cash Flow to Firm (FCFF) |
-113 |
133 |
19 |
Operating Cash Flow to CapEx |
0.00% |
0.00% |
0.00% |
Free Cash Flow to Firm to Interest Expense |
-4.47 |
4.31 |
0.67 |
Operating Cash Flow to Interest Expense |
3.03 |
2.22 |
2.44 |
Operating Cash Flow Less CapEx to Interest Expense |
3.03 |
2.22 |
2.44 |
Efficiency Ratios |
- |
- |
- |
Asset Turnover |
0.08 |
0.08 |
0.09 |
Fixed Asset Turnover |
0.11 |
0.11 |
0.11 |
Capital & Investment Metrics |
- |
- |
- |
Invested Capital |
1,343 |
1,217 |
1,202 |
Invested Capital Turnover |
0.09 |
0.09 |
0.09 |
Increase / (Decrease) in Invested Capital |
126 |
-126 |
-15 |
Enterprise Value (EV) |
1,280 |
1,363 |
1,249 |
Market Capitalization |
517 |
662 |
516 |
Book Value per Share |
$8.52 |
$7.76 |
$6.87 |
Tangible Book Value per Share |
$6.17 |
$5.55 |
$4.71 |
Total Capital |
1,343 |
1,217 |
1,202 |
Total Debt |
694 |
611 |
646 |
Total Long-Term Debt |
58 |
26 |
14 |
Net Debt |
672 |
604 |
636 |
Capital Expenditures (CapEx) |
0.00 |
0.00 |
0.00 |
Net Nonoperating Expense (NNE) |
-6.75 |
-15 |
-2.49 |
Net Nonoperating Obligations (NNO) |
694 |
611 |
646 |
Total Depreciation and Amortization (D&A) |
60 |
61 |
58 |
Earnings Adjustments |
- |
- |
- |
Adjusted Basic Earnings per Share |
$0.20 |
$0.23 |
$0.01 |
Adjusted Weighted Average Basic Shares Outstanding |
65.46M |
65.55M |
65.94M |
Adjusted Diluted Earnings per Share |
$0.20 |
$0.23 |
$0.01 |
Adjusted Weighted Average Diluted Shares Outstanding |
65.46M |
65.55M |
65.94M |
Adjusted Basic & Diluted Earnings per Share |
$0.00 |
$0.00 |
$0.00 |
Adjusted Weighted Average Basic & Diluted Shares Outstanding |
65.53M |
65.57M |
66.87M |
Normalized Net Operating Profit after Tax (NOPAT) |
9.52 |
4.96 |
3.05 |
Normalized NOPAT Margin |
8.49% |
4.50% |
2.77% |
Pre Tax Income Margin |
11.82% |
6.39% |
3.82% |
Debt Service Ratios |
- |
- |
- |
EBIT to Interest Expense |
0.52 |
0.23 |
0.15 |
NOPAT to Interest Expense |
0.52 |
0.23 |
0.15 |
EBIT Less CapEx to Interest Expense |
0.52 |
0.23 |
0.15 |
NOPAT Less CapEx to Interest Expense |
0.52 |
0.23 |
0.15 |
Payout Ratios |
- |
- |
- |
Dividend Payout Ratio |
321.27% |
298.37% |
981.62% |
Augmented Payout Ratio |
321.27% |
298.37% |
981.62% |
Quarterly Metrics And Ratios for Global Medical REIT
This table displays calculated financial ratios and metrics derived from Global Medical REIT's official financial filings.
Metric |
|
Q3 2022 |
Q4 2022 |
Q1 2023 |
Q2 2023 |
Q3 2023 |
Q4 2023 |
Q1 2024 |
Q2 2024 |
Q3 2024 |
Q4 2024 |
Growth Metrics |
|
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
Revenue Growth |
|
13.08% |
37.66% |
3.27% |
-1.46% |
-0.37% |
-8.01% |
0.96% |
-2.27% |
-4.62% |
6.19% |
EBITDA Growth |
|
2.57% |
39.75% |
-3.91% |
-8.70% |
-5.15% |
-7.83% |
-1.97% |
-5.38% |
-8.93% |
-18.72% |
EBIT Growth |
|
-38.97% |
406.81% |
-60.62% |
-63.72% |
-22.34% |
-23.17% |
37.09% |
2.88% |
-38.36% |
-178.22% |
NOPAT Growth |
|
-38.97% |
-58.19% |
-60.62% |
-63.72% |
-22.34% |
-23.17% |
37.09% |
2.88% |
-38.36% |
-154.76% |
Net Income Growth |
|
86.83% |
-66.34% |
-49.30% |
269.77% |
-51.81% |
-70.17% |
6.49% |
-113.77% |
-29.84% |
433.39% |
EPS Growth |
|
100.00% |
-83.33% |
-75.00% |
500.00% |
-58.33% |
-200.00% |
0.00% |
-127.78% |
-40.00% |
300.00% |
Operating Cash Flow Growth |
|
-1.58% |
5.93% |
-4.05% |
-23.87% |
-9.00% |
-1.00% |
-9.37% |
5.87% |
-2.18% |
13.23% |
Free Cash Flow Firm Growth |
|
11.53% |
17.31% |
49.54% |
127.14% |
164.20% |
202.67% |
237.84% |
73.77% |
-45.40% |
-88.85% |
Invested Capital Growth |
|
14.57% |
10.36% |
6.46% |
-3.23% |
-7.82% |
-9.39% |
-8.01% |
-5.88% |
-4.62% |
-1.23% |
Revenue Q/Q Growth |
|
0.52% |
-0.71% |
-1.00% |
-0.27% |
1.63% |
-8.33% |
8.67% |
-3.47% |
-0.81% |
2.06% |
EBITDA Q/Q Growth |
|
-1.16% |
-3.52% |
-2.04% |
-2.26% |
2.68% |
-6.24% |
4.18% |
-5.65% |
-1.17% |
-16.32% |
EBIT Q/Q Growth |
|
-14.55% |
-43.62% |
-8.61% |
-17.59% |
82.89% |
-44.22% |
63.07% |
-38.16% |
9.57% |
-170.79% |
NOPAT Q/Q Growth |
|
-14.55% |
-43.62% |
-8.61% |
-17.59% |
82.89% |
-44.22% |
63.07% |
-38.16% |
9.57% |
-149.55% |
Net Income Q/Q Growth |
|
161.58% |
-81.58% |
17.65% |
552.42% |
-65.91% |
-88.60% |
319.96% |
-184.36% |
273.72% |
-13.33% |
EPS Q/Q Growth |
|
300.00% |
-91.67% |
0.00% |
1,700.00% |
-72.22% |
-120.00% |
200.00% |
-600.00% |
160.00% |
-33.33% |
Operating Cash Flow Q/Q Growth |
|
-22.01% |
-0.03% |
-13.86% |
13.36% |
-6.78% |
8.75% |
-21.14% |
32.43% |
-13.87% |
25.89% |
Free Cash Flow Firm Q/Q Growth |
|
-5.20% |
26.61% |
36.88% |
155.69% |
148.87% |
17.36% |
-15.26% |
-29.79% |
-21.81% |
-76.03% |
Invested Capital Q/Q Growth |
|
3.71% |
-1.05% |
-1.68% |
-4.10% |
-1.20% |
-2.73% |
-0.18% |
-1.88% |
0.12% |
0.72% |
Profitability Metrics |
|
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
EBITDA Margin |
|
64.91% |
63.07% |
62.40% |
61.16% |
61.79% |
63.20% |
60.59% |
59.22% |
59.00% |
48.37% |
EBIT Margin |
|
11.52% |
6.54% |
6.04% |
4.99% |
8.98% |
5.46% |
8.20% |
5.25% |
5.80% |
-4.02% |
Profit (Net Income) Margin |
|
35.26% |
6.54% |
7.77% |
50.84% |
17.06% |
2.12% |
8.20% |
-7.16% |
12.55% |
10.65% |
Tax Burden Percent |
|
306.14% |
100.00% |
128.73% |
1,019.19% |
189.98% |
38.83% |
100.00% |
-136.41% |
216.26% |
-264.77% |
Interest Burden Percent |
|
100.00% |
100.00% |
100.00% |
100.00% |
100.00% |
100.00% |
100.00% |
100.00% |
100.00% |
100.00% |
Effective Tax Rate |
|
0.00% |
0.00% |
0.00% |
0.00% |
0.00% |
0.00% |
0.00% |
0.00% |
0.00% |
0.00% |
Return on Invested Capital (ROIC) |
|
0.95% |
0.57% |
0.53% |
0.44% |
0.77% |
0.47% |
0.71% |
0.47% |
0.51% |
-0.26% |
ROIC Less NNEP Spread (ROIC-NNEP) |
|
2.03% |
0.57% |
0.61% |
2.43% |
1.12% |
0.34% |
0.71% |
-0.08% |
0.81% |
0.33% |
Return on Net Nonoperating Assets (RNNOA) |
|
1.95% |
0.57% |
0.61% |
2.42% |
1.13% |
0.35% |
0.76% |
-0.08% |
0.84% |
0.36% |
Return on Equity (ROE) |
|
2.90% |
1.14% |
1.14% |
2.85% |
1.91% |
0.82% |
1.48% |
0.39% |
1.35% |
0.11% |
Cash Return on Invested Capital (CROIC) |
|
-12.33% |
-8.82% |
-5.42% |
3.92% |
8.71% |
10.40% |
8.95% |
6.68% |
5.28% |
1.59% |
Operating Return on Assets (OROA) |
|
0.91% |
0.55% |
0.51% |
0.42% |
0.75% |
0.45% |
0.69% |
0.45% |
0.49% |
-0.35% |
Return on Assets (ROA) |
|
2.78% |
0.55% |
0.66% |
4.27% |
1.42% |
0.18% |
0.69% |
-0.61% |
1.07% |
0.93% |
Return on Common Equity (ROCE) |
|
2.50% |
0.98% |
0.98% |
2.44% |
1.63% |
0.70% |
1.25% |
0.33% |
1.14% |
0.09% |
Return on Equity Simple (ROE_SIMPLE) |
|
3.64% |
0.00% |
2.92% |
4.56% |
3.77% |
0.00% |
3.80% |
1.03% |
0.79% |
0.00% |
Net Operating Profit after Tax (NOPAT) |
|
3.28 |
1.85 |
1.69 |
1.39 |
2.54 |
1.42 |
2.31 |
1.43 |
1.57 |
-0.78 |
NOPAT Margin |
|
11.52% |
6.54% |
6.04% |
4.99% |
8.98% |
5.46% |
8.20% |
5.25% |
5.80% |
-2.82% |
Net Nonoperating Expense Percent (NNEP) |
|
-1.08% |
0.00% |
-0.08% |
-1.99% |
-0.35% |
0.13% |
0.00% |
0.55% |
-0.29% |
-0.59% |
SG&A Expenses to Revenue |
|
0.00% |
0.00% |
0.00% |
0.00% |
0.00% |
0.00% |
0.00% |
0.00% |
0.00% |
0.00% |
Operating Expenses to Revenue |
|
88.48% |
93.46% |
93.96% |
95.01% |
91.02% |
94.54% |
91.80% |
94.75% |
94.20% |
104.02% |
Earnings before Interest and Taxes (EBIT) |
|
3.28 |
1.85 |
1.69 |
1.39 |
2.54 |
1.42 |
2.31 |
1.43 |
1.57 |
-1.11 |
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA) |
|
18 |
18 |
17 |
17 |
18 |
16 |
17 |
16 |
16 |
13 |
Valuation Ratios |
|
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
Price to Book Value (P/BV) |
|
0.83 |
0.93 |
0.99 |
1.01 |
1.01 |
1.30 |
1.12 |
1.24 |
1.39 |
1.12 |
Price to Tangible Book Value (P/TBV) |
|
1.14 |
1.28 |
1.39 |
1.37 |
1.38 |
1.82 |
1.58 |
1.76 |
2.01 |
1.64 |
Price to Revenue (P/Rev) |
|
4.57 |
4.62 |
4.73 |
4.87 |
4.80 |
6.01 |
5.08 |
5.42 |
5.99 |
4.68 |
Price to Earnings (P/E) |
|
28.46 |
38.84 |
47.19 |
26.21 |
33.73 |
44.77 |
37.61 |
0.00 |
0.00 |
635.91 |
Dividend Yield |
|
11.47% |
10.64% |
10.29% |
10.04% |
10.21% |
8.32% |
9.82% |
9.25% |
8.48% |
10.88% |
Earnings Yield |
|
3.51% |
2.57% |
2.12% |
3.82% |
2.96% |
2.23% |
2.66% |
0.00% |
0.00% |
0.16% |
Enterprise Value to Invested Capital (EV/IC) |
|
0.91 |
0.95 |
0.98 |
0.99 |
0.99 |
1.12 |
1.04 |
1.09 |
1.14 |
1.04 |
Enterprise Value to Revenue (EV/Rev) |
|
11.88 |
11.43 |
11.47 |
11.11 |
11.00 |
12.38 |
11.47 |
11.82 |
12.60 |
11.34 |
Enterprise Value to EBITDA (EV/EBITDA) |
|
18.21 |
17.51 |
17.89 |
17.67 |
17.72 |
19.92 |
18.61 |
19.32 |
20.83 |
19.97 |
Enterprise Value to EBIT (EV/EBIT) |
|
114.82 |
96.67 |
121.65 |
152.47 |
165.58 |
193.58 |
165.24 |
168.31 |
202.97 |
297.16 |
Enterprise Value to NOPAT (EV/NOPAT) |
|
78.37 |
96.67 |
121.65 |
152.47 |
165.58 |
193.58 |
165.24 |
168.31 |
202.97 |
297.16 |
Enterprise Value to Operating Cash Flow (EV/OCF) |
|
16.41 |
16.73 |
17.07 |
17.80 |
18.02 |
19.92 |
18.92 |
19.08 |
20.20 |
17.83 |
Enterprise Value to Free Cash Flow (EV/FCFF) |
|
0.00 |
0.00 |
0.00 |
24.77 |
10.89 |
10.24 |
11.17 |
15.79 |
21.18 |
65.04 |
Leverage & Solvency |
|
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
Debt to Equity |
|
1.04 |
1.07 |
1.10 |
0.97 |
0.97 |
1.01 |
1.03 |
1.06 |
1.11 |
1.16 |
Long-Term Debt to Equity |
|
0.09 |
0.09 |
0.09 |
0.09 |
0.09 |
0.04 |
0.04 |
0.03 |
0.03 |
0.03 |
Financial Leverage |
|
0.96 |
0.99 |
1.00 |
1.00 |
1.01 |
1.04 |
1.07 |
1.02 |
1.04 |
1.08 |
Leverage Ratio |
|
2.05 |
2.06 |
2.07 |
2.08 |
2.09 |
2.12 |
2.15 |
2.10 |
2.12 |
2.17 |
Compound Leverage Factor |
|
2.05 |
2.06 |
2.07 |
2.08 |
2.09 |
2.12 |
2.15 |
2.10 |
2.12 |
2.17 |
Debt to Total Capital |
|
51.04% |
51.68% |
52.41% |
49.36% |
49.36% |
50.22% |
50.85% |
51.48% |
52.69% |
53.75% |
Short-Term Debt to Total Capital |
|
46.77% |
47.38% |
48.07% |
44.85% |
44.82% |
48.09% |
48.74% |
50.25% |
51.48% |
52.55% |
Long-Term Debt to Total Capital |
|
4.27% |
4.29% |
4.34% |
4.51% |
4.54% |
2.13% |
2.11% |
1.23% |
1.21% |
1.20% |
Preferred Equity to Total Capital |
|
5.52% |
5.58% |
5.68% |
5.92% |
5.99% |
6.16% |
6.17% |
6.29% |
6.28% |
6.24% |
Noncontrolling Interests to Total Capital |
|
1.17% |
1.20% |
1.19% |
1.72% |
1.77% |
1.83% |
1.82% |
1.84% |
1.85% |
1.81% |
Common Equity to Total Capital |
|
42.27% |
41.54% |
40.72% |
43.00% |
42.88% |
41.79% |
41.16% |
40.39% |
39.18% |
38.20% |
Debt to EBITDA |
|
10.18 |
9.49 |
9.56 |
8.83 |
8.85 |
8.93 |
9.07 |
9.14 |
9.59 |
10.33 |
Net Debt to EBITDA |
|
9.87 |
9.19 |
9.25 |
8.56 |
8.60 |
8.82 |
8.95 |
9.01 |
9.44 |
10.18 |
Long-Term Debt to EBITDA |
|
0.85 |
0.79 |
0.79 |
0.81 |
0.81 |
0.38 |
0.38 |
0.22 |
0.22 |
0.23 |
Debt to NOPAT |
|
43.81 |
52.41 |
65.02 |
76.21 |
82.68 |
86.80 |
80.56 |
79.61 |
93.42 |
153.73 |
Net Debt to NOPAT |
|
42.47 |
50.73 |
62.90 |
73.84 |
80.34 |
85.75 |
79.45 |
78.48 |
92.01 |
151.43 |
Long-Term Debt to NOPAT |
|
3.66 |
4.35 |
5.39 |
6.96 |
7.61 |
3.68 |
3.35 |
1.90 |
2.15 |
3.43 |
Noncontrolling Interest Sharing Ratio |
|
13.93% |
14.05% |
14.07% |
14.48% |
14.48% |
15.00% |
15.32% |
15.88% |
16.20% |
16.69% |
Liquidity Ratios |
|
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
Cash Flow Metrics |
|
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
Free Cash Flow to Firm (FCFF) |
|
-169 |
-124 |
-78 |
44 |
109 |
128 |
108 |
76 |
59 |
14 |
Operating Cash Flow to CapEx |
|
0.00% |
0.00% |
0.00% |
0.00% |
0.00% |
0.00% |
0.00% |
0.00% |
0.00% |
0.00% |
Free Cash Flow to Firm to Interest Expense |
|
-24.31 |
-15.41 |
-9.48 |
5.16 |
15.16 |
18.26 |
15.69 |
10.85 |
8.20 |
1.88 |
Operating Cash Flow to Interest Expense |
|
2.63 |
2.27 |
1.91 |
2.11 |
2.32 |
2.60 |
2.07 |
2.71 |
2.25 |
2.71 |
Operating Cash Flow Less CapEx to Interest Expense |
|
2.63 |
2.27 |
1.91 |
2.11 |
2.32 |
2.60 |
2.07 |
2.71 |
2.25 |
2.71 |
Efficiency Ratios |
|
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
Asset Turnover |
|
0.08 |
0.08 |
0.09 |
0.08 |
0.08 |
0.08 |
0.08 |
0.09 |
0.09 |
0.09 |
Fixed Asset Turnover |
|
0.10 |
0.11 |
0.11 |
0.11 |
0.11 |
0.11 |
0.11 |
0.11 |
0.11 |
0.11 |
Capital & Investment Metrics |
|
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
Invested Capital |
|
1,357 |
1,343 |
1,321 |
1,267 |
1,251 |
1,217 |
1,215 |
1,192 |
1,193 |
1,202 |
Invested Capital Turnover |
|
0.08 |
0.09 |
0.09 |
0.09 |
0.09 |
0.09 |
0.09 |
0.09 |
0.09 |
0.09 |
Increase / (Decrease) in Invested Capital |
|
173 |
126 |
80 |
-42 |
-106 |
-126 |
-106 |
-74 |
-58 |
-15 |
Enterprise Value (EV) |
|
1,239 |
1,280 |
1,295 |
1,251 |
1,237 |
1,363 |
1,267 |
1,297 |
1,366 |
1,249 |
Market Capitalization |
|
477 |
517 |
535 |
548 |
540 |
662 |
561 |
596 |
650 |
516 |
Book Value per Share |
|
$8.76 |
$8.52 |
$8.21 |
$8.31 |
$8.18 |
$7.76 |
$7.63 |
$7.34 |
$7.13 |
$6.87 |
Tangible Book Value per Share |
|
$6.41 |
$6.17 |
$5.85 |
$6.09 |
$5.98 |
$5.55 |
$5.42 |
$5.17 |
$4.94 |
$4.71 |
Total Capital |
|
1,357 |
1,343 |
1,321 |
1,267 |
1,251 |
1,217 |
1,215 |
1,192 |
1,193 |
1,202 |
Total Debt |
|
693 |
694 |
692 |
625 |
618 |
611 |
618 |
614 |
629 |
646 |
Total Long-Term Debt |
|
58 |
58 |
57 |
57 |
57 |
26 |
26 |
15 |
14 |
14 |
Net Debt |
|
672 |
672 |
670 |
606 |
600 |
604 |
609 |
605 |
619 |
636 |
Capital Expenditures (CapEx) |
|
0.00 |
0.00 |
0.00 |
0.00 |
0.00 |
0.00 |
0.00 |
0.00 |
0.00 |
0.00 |
Net Nonoperating Expense (NNE) |
|
-6.75 |
0.00 |
-0.49 |
-13 |
-2.29 |
0.87 |
0.00 |
3.38 |
-1.82 |
-3.72 |
Net Nonoperating Obligations (NNO) |
|
693 |
694 |
692 |
625 |
618 |
611 |
618 |
614 |
629 |
646 |
Total Depreciation and Amortization (D&A) |
|
15 |
16 |
16 |
16 |
15 |
15 |
15 |
15 |
14 |
14 |
Earnings Adjustments |
|
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
Adjusted Basic Earnings per Share |
|
$0.12 |
$0.01 |
$0.01 |
$0.18 |
$0.05 |
($0.01) |
$0.01 |
($0.05) |
$0.03 |
$0.02 |
Adjusted Weighted Average Basic Shares Outstanding |
|
65.52M |
65.46M |
65.53M |
65.54M |
65.57M |
65.55M |
65.57M |
65.59M |
65.74M |
65.94M |
Adjusted Diluted Earnings per Share |
|
$0.12 |
$0.01 |
$0.01 |
$0.18 |
$0.05 |
($0.01) |
$0.01 |
($0.05) |
$0.03 |
$0.02 |
Adjusted Weighted Average Diluted Shares Outstanding |
|
65.52M |
65.46M |
65.53M |
65.54M |
65.57M |
65.55M |
65.57M |
65.59M |
65.74M |
65.94M |
Adjusted Basic & Diluted Earnings per Share |
|
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
Adjusted Weighted Average Basic & Diluted Shares Outstanding |
|
65.52M |
65.53M |
65.53M |
65.56M |
65.56M |
65.57M |
65.59M |
65.59M |
66.80M |
66.87M |
Normalized Net Operating Profit after Tax (NOPAT) |
|
2.37 |
1.37 |
1.21 |
0.98 |
1.78 |
0.99 |
1.62 |
1.00 |
1.10 |
-0.67 |
Normalized NOPAT Margin |
|
8.34% |
4.86% |
4.33% |
3.50% |
6.28% |
3.82% |
5.74% |
3.68% |
4.06% |
-2.42% |
Pre Tax Income Margin |
|
11.52% |
6.54% |
6.04% |
4.99% |
8.98% |
5.46% |
8.20% |
5.25% |
5.80% |
-4.02% |
Debt Service Ratios |
|
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
EBIT to Interest Expense |
|
0.47 |
0.23 |
0.20 |
0.16 |
0.35 |
0.20 |
0.34 |
0.20 |
0.22 |
-0.15 |
NOPAT to Interest Expense |
|
0.47 |
0.23 |
0.20 |
0.16 |
0.35 |
0.20 |
0.34 |
0.20 |
0.22 |
-0.10 |
EBIT Less CapEx to Interest Expense |
|
0.47 |
0.23 |
0.20 |
0.16 |
0.35 |
0.20 |
0.34 |
0.20 |
0.22 |
-0.15 |
NOPAT Less CapEx to Interest Expense |
|
0.47 |
0.23 |
0.20 |
0.16 |
0.35 |
0.20 |
0.34 |
0.20 |
0.22 |
-0.10 |
Payout Ratios |
|
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
Dividend Payout Ratio |
|
268.92% |
321.27% |
360.20% |
228.49% |
280.81% |
298.37% |
297.57% |
1,136.55% |
1,519.49% |
981.62% |
Augmented Payout Ratio |
|
268.92% |
321.27% |
360.20% |
228.49% |
280.81% |
298.37% |
297.57% |
1,136.55% |
1,519.49% |
981.62% |
Key Financial Trends
Global Medical REIT (NYSE: GMRE) has shown a mixed financial performance over the last four years, with seasonal and yearly fluctuations observed in net income, revenues, expenses, and cash flows. Below is a summary of notable trends and key financial highlights from the Q4 2022 through Q4 2024 period:
- Revenue growth: Total revenue increased from around $28.2 million in Q4 2022 to $27.6 million in Q4 2024, showing relative stability with some quarterly fluctuations.
- Strong non-interest income: Other non-interest income consistently contributed over $32 million per quarter, reaching $34.95 million in Q4 2024, supporting overall revenue despite negative net interest income.
- Operating cash flow improvement: Net cash from continuing operating activities rose from $18.3 million in Q4 2022 to $20.5 million in Q4 2024, indicating solid cash generation from core operations.
- Manageable dividend payout: Common dividends per share remained steady at $0.21 per quarter throughout the period, reflecting consistent cash distributions to shareholders.
- Reduction in restructuring charges: Restructuring charges have declined, with $155,000 in Q4 2024 compared to earlier periods like $112,000 in Q3 2022 and $42,000 in Q1 2023, potentially lowering one-time costs.
- Consistent depreciation and amortization: These non-cash expenses have been steady near $10 million and $3.4-$4.5 million quarterly respectively, impacting net income but reflecting asset depreciation.
- Stable share count: Weighted average diluted shares outstanding hovered around 65.5-66.8 million shares, indicating limited dilution and stability in share base.
- Cash and restricted cash balances fluctuated: Cash and equivalents show volatility, ranging from around $1.3 million in Q1 2024 to $5.7 million in Q3 2024, possibly linked to investing and financing activities.
- Debt issuance and repayments active: The company frequently issued and repaid short-term and long-term debt amounts exceeding $40-$60 million in some quarters, reflecting active capital management strategies.
- Continued negative net interest income: GMRE consistently posted a net interest expense each quarter, around $7 million, reflecting high interest costs outweighing any interest income.
- Net income volatility: The company reported swings from losses (e.g., -$3.1 million common shareholder loss in Q2 2024) to positive net income (e.g., $1.37 million in Q4 2024), indicating earnings instability.
- High operating expenses: Other operating expenses ranged around $10-15 million per quarter, sometimes growing, which pressures profitability.
- Large fluctuations in investing cash flows: Significant purchases and sales of investment securities contributed to a net negative investing cash flow in most quarters (e.g., -$19.5 million in Q4 2024), impacting liquidity.
- Decline in equity balances: Total equity and noncontrolling interests dropped from nearly $664 million in Q1 2022 to approximately $565 million in Q3 2024, suggesting equity erosion over time.
Summary: Global Medical REIT remains operationally stable with good cash flow from continuing operations and consistent dividend payouts to shareholders. However, it faces challenges including persistent net interest expense due to debt costs, volatility in net income, and equity shrinkage. Investors should watch for improvements in profitability and debt management as key indicators for future performance.
08/29/25 05:46 AM ETAI Generated. May Contain Errors.